| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2004.12.133 |
| P698 | PubMed publication ID | 15459216 |
| P50 | author | Stephan Stilgenbauer | Q47158807 |
| Peter Lichter | Q2076661 | ||
| P2093 | author name string | Norbert Schweifer | |
| Hartmut Döhner | |||
| Christian Stratowa | |||
| Norbert Kraut | |||
| Christian Haslinger | |||
| Roger Abseher | |||
| P2860 | cites work | p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia | Q37535238 |
| P433 | issue | 19 | |
| P921 | main subject | B-cell chronic lymphocytic leukemia | Q11829285 |
| P304 | page(s) | 3937-3949 | |
| P577 | publication date | 2004-10-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status | |
| P478 | volume | 22 |
| Q110949997 | A Sparse-Modeling Based Approach for Class Specific Feature Selection |
| Q37438957 | A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia |
| Q37482750 | A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment. |
| Q35643020 | ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression |
| Q38196695 | BTB-ZF transcription factors, a growing family of regulators of early and late B-cell development |
| Q36579130 | CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes |
| Q47114281 | Cancer-type dependent expression of CK2 transcripts. |
| Q27304652 | Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease |
| Q33382608 | Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia |
| Q36358326 | Chromosome abnormalities with prognostic impact in B-cell chronic lymphocytic leukemia |
| Q80932425 | Chronic lymphocytic leukaemia |
| Q34612039 | Clinical and biological relevance of genomic heterogeneity in chronic lymphocytic leukemia |
| Q45988365 | Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. |
| Q35053674 | Clinical proteomics: present and future prospects. |
| Q30992577 | Clustering of Expression Data in Chronic Lymphocytic Leukemia Reveals New Molecular Subdivisions |
| Q51578542 | Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14)(q |
| Q81099032 | Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping |
| Q33742884 | Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in males |
| Q83948553 | Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks |
| Q26853482 | Coordination of nutrient availability and utilization by MAX- and MLX-centered transcription networks |
| Q94101744 | Current Awareness on Comparative and Functional Genomics |
| Q83159498 | Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression |
| Q35653850 | Developing Molecular Signatures for Chronic Lymphocytic Leukemia |
| Q34316489 | Dysregulation of the Mitogen Granulin in Human Cancer through the miR-15/107 microRNA Gene Group |
| Q34217900 | Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia |
| Q39592668 | Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling. |
| Q43860255 | Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20. |
| Q35162589 | Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia |
| Q89629062 | Expression of the muscle-associated gene MYF6 in hairy cell leukemia |
| Q34219505 | Gene Expression and Serum Cytokine Profiling of Low Stage CLL Identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as Regulators of Cell Proliferation, Survival and Migration |
| Q35810815 | Gene expression and splicing alterations analyzed by high throughput RNA sequencing of chronic lymphocytic leukemia specimens |
| Q33587644 | Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia |
| Q54646999 | Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genes. |
| Q37207766 | Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA |
| Q39819083 | Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia. |
| Q33744997 | Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go |
| Q36115671 | Genetics and molecular biology of chronic lymphocytic leukemia |
| Q27309985 | Heat-shock factor 2 is a suppressor of prostate cancer invasion. |
| Q33813862 | High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival |
| Q35906329 | High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome |
| Q34103991 | High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle |
| Q35021249 | Higher gene expression variability in the more aggressive subtype of chronic lymphocytic leukemia |
| Q37515512 | HtrA serine proteases as potential therapeutic targets in cancer |
| Q33634389 | Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients. |
| Q47340390 | Imprecision and DNA Break Repair Biased Towards Incompatible End Joining in Leukemia. |
| Q43892008 | Inhibition of Ubc13-mediated Ubiquitination by GPS2 Regulates Multiple Stages of B Cell Development. |
| Q31077729 | Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms |
| Q34924406 | LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients |
| Q92565531 | Meta-analysis of gene expression alterations and clinical significance of the HECT domain-containing ubiquitin ligase HUWE1 in cancer |
| Q91806615 | Methionine is a metabolic dependency of tumor-initiating cells |
| Q60197192 | Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia |
| Q64098709 | Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer |
| Q34479078 | Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma |
| Q35794466 | NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL |
| Q33317040 | Negative selection of chronic lymphocytic leukaemia cells using a bifunctional rosette-based antibody cocktail |
| Q34996082 | Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor |
| Q48222706 | Overexpression of the proneural transcription factor ASCL1 in chronic lymphocytic leukemia with a t(12;14)(q23.2;q32.3). |
| Q51219604 | PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions. |
| Q37341168 | Peptidyl-prolyl isomerase Pin1 markedly enhances the oncogenic activity of the rel proteins in the nuclear factor-kappaB family |
| Q38514215 | Positional gene enrichment analysis of gene sets for high-resolution identification of overrepresented chromosomal regions |
| Q40420609 | Protein expression analysis of chromosome 12 candidate genes in chronic lymphocytic leukemia (CLL). |
| Q34255118 | Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk |
| Q49788400 | Proteomics profiling of CLL versus healthy B-cells identifies putative therapeutic targets and a subtype-independent signature of spliceosome dysregulation |
| Q81639776 | Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo |
| Q35852820 | Regulatory network reconstruction reveals genes with prognostic value for chronic lymphocytic leukemia |
| Q33330596 | SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. |
| Q33779931 | Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. |
| Q37327060 | Sex-specific genomic biomarkers for individualized treatment of life-threatening diseases |
| Q39758487 | Smad3 protein levels are modulated by Ras activity and during the cell cycle to dictate transforming growth factor-beta responses |
| Q35791336 | Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia |
| Q36286867 | Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression |
| Q28388451 | Suppression of survival signalling pathways by the phosphatase PHLPP |
| Q33688989 | Systematic analysis of gene expression alterations and clinical outcomes of adenylate cyclase-associated protein in cancer |
| Q61450684 | Systematic tracking of altered modules identifies the key biomarkers involved in chronic lymphocytic leukemia |
| Q37495044 | Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination |
| Q37591262 | Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells |
| Q33974256 | The projection score--an evaluation criterion for variable subset selection in PCA visualization |
| Q33518516 | The use of knockout mice reveals a synergistic role of the Vav1 and Rasgrf2 gene deficiencies in lymphomagenesis and metastasis |
| Q35325738 | Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia. |
| Q59797169 | Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways |
| Q41145371 | Voltage-gated calcium channels: Novel targets for cancer therapy |
Search more.